What is HC Wainwright’s Estimate for DBVT Q1 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of DBV Technologies in a research report issued on Friday, March 27th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.14) per share for the quarter. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS and FY2030 earnings at $1.75 EPS.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96). DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The company had revenue of $0.64 million during the quarter, compared to the consensus estimate of $1.06 million.

A number of other equities research analysts have also recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Citizens Jmp lifted their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Guggenheim reaffirmed a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.65.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $20.00 on Monday. The stock has a fifty day simple moving average of $21.58 and a two-hundred day simple moving average of $17.33. DBV Technologies has a 1-year low of $5.30 and a 1-year high of $26.18. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -3.83 and a beta of -0.97.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Artisan Partners Limited Partnership boosted its stake in DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after buying an additional 3,257,135 shares during the period. Vivo Capital LLC increased its stake in DBV Technologies by 133.4% in the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after acquiring an additional 1,407,120 shares during the last quarter. Siren L.L.C. bought a new position in DBV Technologies in the 4th quarter worth about $35,606,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC bought a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

Trending Headlines about DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.